Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development
19 Setembro 2023 - 9:00AM
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage
oncology company developing first-in-classi therapeutics that
combine both targeted and immune-mediated mechanisms, announced
today that executive vice president and chief medical officer, Sam
Whiting, M.D. Ph.D., has expanded his role to include head of
Research and Development.
“Sam is an experienced industry drug developer
whose additional years of academic research and clinical practice
as a medical oncologist at the University of Washington and Fred
Hutchinson Cancer Research Center provide broad insight in to how
to develop drugs that would be integrated into medical practice and
could improve the lives of cancer patients,” said Stephen Brady,
president and chief executive officer of Tempest. “Sam’s abilities
as both a drug developer and internal leader have made him an
important part of our transformation into a promising, later-stage
clinical company that includes our lead program, TPST-1120, the
first randomized data from which showed an exciting improvement
over the standard of care therapy in first-line liver cancer.”
Dr. Whiting added, “Tempest has a scientifically
rigorous and very talented Research and Development team, and I’m
honored to take on this expanded leadership role. Our preclinical
and translational sciences fuel the company’s robust pipeline,
while providing key insight into our clinical programs. I am
excited by the opportunities for synergy between research and
clinical development and what we can achieve together with our
diversified pipeline of first-in-class therapeutics that range from
early discovery all the way to TPST-1120 and its potential in liver
cancer, renal cell carcinoma and beyond.”
Dr. Whiting joined Tempest as executive
vice president and chief medical officer in November 2020, and
assumed the role of chief medical officer and head of research and
development following the departure of Tom Dubensky, Ph.D., who has
become an advisor to the company. Prior to joining Tempest,
Dr. Whiting served as senior vice president of clinical
development at Calithera Biosciences, a clinical-stage biotech
company focused on developing treatments for cancer and other
life-threatening diseases. Before Calithera, Dr. Whiting
served as vice president of research and clinical development at
Gradalis and worked in development of small molecule targeted and
immune-oncology agents at VentiRx Pharmaceuticals and Oncothyreon.
Prior to joining industry, Dr. Whiting served as assistant
professor of medical oncology at the University of Washington,
assistant member of clinical research at the Fred Hutchinson Cancer
Research Center, and clinical head of gastrointestinal oncology at
the Seattle Cancer Care Alliance. Dr. Whiting completed
fellowship training in medical oncology at the Fred Hutchinson
Cancer Research Center. His training in internal medicine was
through the ABIM Research Pathway at the University of Washington.
Dr. Whiting received his B.S. with Honors in Chemistry from
Lewis and Clark College and his M.D. and Ph.D in microbiology in
the Medical Scientist Training Program at the University of
Washington.
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage
oncology company advancing small molecules that combine both
tumor-targeted and immune-mediated mechanisms with the potential to
treat a wide range of tumors. The company has a diverse portfolio
of novel programs ranging from early research to investigation in a
randomized global study in first-line cancer patients. The
company’s two clinical programs, TPST-1120 and TPST-1495, target
PPARα and the prostaglandin E2 receptors, EP2/EP4, respectively,
and are advancing through trials designed to study the agents as
monotherapies and in combination with approved agents. TPST-1495 is
currently being evaluated in combination with pembrolizumab in a
Phase 1b expansion cohort in patients with advanced endometrial
cancer. TPST-1120 is being evaluated in first line treatment of
hepatocellular carcinoma (HCC) in combination with atezolizumab and
bevacizumab, the standard of care for first-line HCC, in a Phase
1b/2 randomized global study where an early data cut demonstrated
positive results in multiple categories; the company expects to
receive the first full data set in the second half of 2023. Tempest
is also developing an orally available inhibitor of TREX1, a target
that controls activation of the cGAS/STING pathway. Tempest is
headquartered in Brisbane, California. More information about
Tempest can be found on the company’s website at
www.tempesttx.com.
Forward-Looking Statements
This press release contains forward-looking
statements (including within the meaning of Section 21E of the
Securities Exchange Act of 1934, as amended, and Section 27A of the
Securities Act of 1933, as amended (the “Securities Act”))
concerning Tempest Therapeutics, Inc. These statements may discuss
goals, intentions, and expectations as to future plans, trends,
events, results of operations or financial condition, or otherwise,
based on current beliefs of the management of Tempest Therapeutics,
as well as assumptions made by, and information currently available
to, management of Tempest Therapeutics. Forward-looking statements
generally include statements that are predictive in nature and
depend upon or refer to future events or conditions, and include
words such as “may,” “will,” “should,” “would,” “could”, “expect,”
“anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,”
“intend,” and other similar expressions. All statements that are
not historical facts are forward-looking statements, including any
statements regarding: the design, initiation, progress, timing,
scope and results of clinical trials; anticipated therapeutic
benefit and regulatory development of Tempest Therapeutic’s product
candidates; the Company’s ability to deliver on potential
value-creating milestones; the Company’s guidance regarding cash
runway, as well as our operational plans. Forward-looking
statements are based on information available to Tempest
Therapeutics as of the date hereof and are not guarantees of future
performance. Any factors may cause differences between current
expectations and actual results, including: unexpected safety or
efficacy data observed during preclinical or clinical trials;
clinical trial site activation or enrollment rates that are lower
than expected; changes in expected or existing competition; changes
in the regulatory environment; and unexpected litigation or other
disputes. Other factors that may cause actual results to differ
from those expressed or implied are discussed in greater detail in
the “Risk Factors” section of the Company’s Quarterly Report on
Form 10-Q for the quarter ended June 30, 2023 and other documents
filed by the Company from time to time with the Securities and
Exchange Commission. Except as required by applicable law, Tempest
Therapeutics undertakes no obligation to revise or update any
forward-looking statement, or to make any other forward-looking
statements, whether as a result of new information, future events
or otherwise. These forward-looking statements should not be relied
upon as representing Tempest Therapeutics’ views as of any date
subsequent to the date of this press release and should not be
relied upon as prediction of future events. In light of the
foregoing, investors are urged not to rely on any forward-looking
statement in reaching any conclusion or making any investment
decision about any securities of Tempest Therapeutics.
Investor Contacts:
Sylvia WheelerWheelhouse Life Science
Advisorsswheeler@wheelhouselsa.com
Aljanae Reynolds Wheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
Tempest Therpeutics (NASDAQ:TPST)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Tempest Therpeutics (NASDAQ:TPST)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024